|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Table A25–1 Incidence of Group B Streptococcus Infection in Noninfants and Nonpregnant Women
with GBS experience invasive disease (e.g., bacteremia, sepsis, soft tissue infections) associated with 19 days at an HUI of .66. See Table A25–2. COST INCURRED BY DISEASETable A25–3 summarizes the health care costs incurred by GBS infections. For the purposes of the calculations in this report, it was assumed that GBS infections in pregnant women are associated with additional hospitalization at the time of delivery and associated inpatient and outpatient physician visits and medication. Costs are also included for screening for GBS and chemoprophylaxis of pregnant women. It was estimated that all nonpregnant adults with invasive GBS disease require hospitalization (including inpatient physician visits) and outpatient services as well. For the calculation in this report, it was assumed that all infants with GBS require hospitalization, including multiple inpatient physician visits and diagnostics. It was assumed that a small percentage of infants with GBS meningitis will require long-term care for 10 years until death. VACCINE DEVELOPMENTThe committee assumed that it will take 7 years until licensure of a GBS vaccine and that $300 million needs to be invested for approval for use in nonpregnant people, and an additional $100 million needs to be invested for that same vaccine to be used in pregnant women. Special considerations regarding
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
